NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Forecast, Price & News

$7.51

+0.36 (+5.03%)

(As of 09/29/2023 ET)

Compare

Today's Range: $7.08
▼
$7.55
50-Day Range: $7.15
▼
$8.91
52-Week Range: $7.02
▼
$10.85

Volume: 117,335 shs
Average Volume: 67,407 shs
Market Capitalization: $199.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.50

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 119.7% Upside
$16.50 Price Target
Short Interest: Bearish
7.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$79,500 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

705th out of 972 stocks

Biological Products, Except Diagnostic Industry

109th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.50, Fennec Pharmaceuticals has a forecasted upside of 119.7% from its current price of $7.51.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.28% of the float of Fennec Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 27.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Fennec Pharmaceuticals has recently decreased by 3.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FENC.

3.3

News and Social Media Coverage

News Sentiment
Fennec Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Fennec Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
2 people have searched for FENC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,500.00 in company stock.
Percentage Held by Insiders
11.25% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.06% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Price History

30 days | 90 days | 365 days | Advanced Chart

FENC Stock News Headlines

August 10, 2023 | finance.yahoo.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript

August 4, 2023 | msn.com

HC Wainwright & Co. Maintains Fennec Pharmaceuticals (FENC) Buy Recommendation

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

August 4, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Fennec Pharmaceuticals (FENC)

July 31, 2023 | finance.yahoo.com

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

July 14, 2023 | theglobeandmail.com

Instrument Name Fennec Pharmaceuticals Inc Instrument Symbol (FENC-Q)

June 21, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)

June 14, 2023 | finanznachrichten.de

Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

June 8, 2023 | finance.yahoo.com

Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well

June 6, 2023 | finance.yahoo.com

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

May 17, 2023 | insidermonkey.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2023 Earnings Call Transcript

May 12, 2023 | markets.businessinsider.com

Maxim Group Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)

May 11, 2023 | finanznachrichten.de

Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | msn.com

Recap: Fennec Pharmaceuticals Q1 Earnings

May 11, 2023 | finance.yahoo.com

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023 | investing.com

Fennec Pharma (FRX) Earnings Dates & Reports

May 10, 2023 | msn.com

Earnings Outlook For Fennec Pharmaceuticals

April 27, 2023 | theglobeandmail.com

Closing Bell: Fennec Pharmaceuticals Inc flat on Wednesday (FRX)

April 26, 2023 | theglobeandmail.com

Closing Bell: Fennec Pharmaceuticals Inc flat on Tuesday (FRX)

April 13, 2023 | bizjournals.com

Cipla seeks to dismiss RTP drugmaker's patent lawsuit

April 7, 2023 | msn.com

Cantor Fitzgerald Maintains Fennec Pharmaceuticals (FENC) Overweight Recommendation

April 6, 2023 | markets.businessinsider.com

Analyst Ratings for Fennec Pharmaceuticals

April 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Fennec Pharmaceuticals (FENC) Buy Recommendation

March 31, 2023 | markets.businessinsider.com

Fennec Receives Positive CHMP Opinion For Pedmarqsi In Pediatric Oncology Patients

March 30, 2023 | finanznachrichten.de

Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

March 30, 2023 | markets.businessinsider.com

Craig-Hallum Remains a Buy on Fennec Pharmaceuticals (FENC)

See More Headlines

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FENC
CUSIP: N/A
CIK: 1211583
Web: www.fennecpharma.com
Phone: 919-636-4530
Fax: 919-890-0490
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.50
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +119.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,710,000.00
Net Margins: N/A
Pretax Margin: -528.63%
Return on Equity: -7,266.90%
Return on Assets: -107.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.12
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 130.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.10) per share
Price / Book: -75.10

Miscellaneous

Outstanding Shares: 26,630,000
Free Float: 23,631,000
Market Cap: $199.99 million
Optionable: Optionable
Beta: 0.24

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Rostislav Raykov (Age 42)
Pres, CEO & Director

Mr. Robert C. Andrade (Age 43)
Chief Financial Officer

Mr. Mark Gowland
Controller

Mr. Lei Fang
Pres of Pharstat Inc

Ms. Anne McKay (Age 64)
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.
What is Fennec Pharmaceuticals' stock price forecast for 2023?: 2 brokerages have issued 12-month target prices for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $16.00 to $17.00. On average, they predict the company's share price to reach $16.50 in the next year. This suggests a possible upside of 119.7% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.
How have FENC shares performed in 2023?: Fennec Pharmaceuticals' stock was trading at $9.60 on January 1st, 2023. Since then, FENC shares have decreased by 21.8% and is now trading at $7.51.
View the best growth stocks for 2023 here.
When is Fennec Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 10th 2023.
View our FENC earnings forecast.
How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03. The company had revenue of $3.33 million for the quarter, compared to analysts' expectations of $4.01 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).
What is Fennec Pharmaceuticals' stock symbol?: Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
How do I buy shares of Fennec Pharmaceuticals?: Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fennec Pharmaceuticals' stock price today?: One share of FENC stock can currently be purchased for approximately $7.51.
How much money does Fennec Pharmaceuticals make?: Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $199.99 million and generates $1.53 million in revenue each year. The company earns $-23,710,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.
How can I contact Fennec Pharmaceuticals?: Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial